This study is designed to evaluate the clinical characteristics and the outcomes of the management of gestational trophoblastic disease diagnosed at our hospital. With a retrospective review of hospital record from 1989 to 1998, we analysed 54 cases of gestational trophoblastic disease by the clinical characteristics and the outcomes of management. The results are as follows 1. The incidence of the gestational trophoblastic disease compared with delivery is one per 341 deliveries and is decreasing with time(from one per 252 deliveries at 1989 to one per 694 deliveries at 1998). 2. The most frequent age is 20-29 years old(61,1%). 3, The most frequent gravity and parity is 0-2 times(68.5%) and 0-1 time(79.6%) respectively. 4. The symptoms and signs are amenorrhea(94.4%), vaginal bleeding(74,1%), abdominal pain( 33.3%), hyperemesis gravidarum(25.9%), excessive uterine enlargement(24.1%), anemia(18.5%), hyperthyroidism(7.4%), theca lutein ovarian cyst(3.7%), and preeclampsia (1.9%). 5. We divided the patients by the uterine size for gestational age; large for date 50%, normal for date 44.4%, and small for date 5.6%. 6. The antecedent pregnancies of patients with persistent gestational trophoblastic tumor are hydatidiform mole 87.5%, abortion 12.5% in middle risk group and hydatidiform mole 66.7%, term pregnancy 22.2%, abortion 11,1% in high risk group. 7. We divided the patients with persistent gestational trophoblastic tumor by the FIGO staging system; stage I 70.6%, stage II 5.9%, stage III 11.8%, stage IV 11,8%. 8. The regimens of treatment are consisted of D & E only(59.3%), D & E with prophylactic chemotherapy(9.3%), D & E with chemotherapy(25.9%), and D & E with chemotherapy and hysterectomy(5.6%). Complete remissions are shown in 100% of D & E only and D & E with prophylactic chemotherapy, in 85.7% of D & E with chemotherapy, and in 33.3% of D & E with chemotherapy and hysterectomy. Dividing the patients with persistent gestational trophoblastic tumor by the WHO prognostic scoring system, complete remissions are shown in 75% of middle risk group and in 77.8% of high risk group. 9. The duration of chemotherapy for complete remission is 2.5 cycles & 77.5 days in middle risk group and 4 cycles & 130.1 days in high risk group. 10. The subsequent pregnancies after complete remission of gestational trophoblastic disease are term delivery 81%, spontaneous abortion 9.5%, induced abortion 4.8%, and preterm delivery 4.8%.
Abortion, Induced ; Abortion, Spontaneous ; Drug Therapy ; Female ; Gestational Age ; Gestational Trophoblastic Disease* ; Gravitation ; Hospital Records ; Humans ; Hydatidiform Mole ; Hysterectomy ; Incidence ; Lutein ; Parity ; Pre-Eclampsia ; Pregnancy ; Retrospective Studies ; Trophoblastic Neoplasms

No abstract available.
Fever* ; Infectious Mononucleosis* ; Lymphatic Diseases*

No abstract available.
Calcium* ; Homeostasis* ; Phosphorus*

No abstract available.
Atherosclerosis* ; Insulin Resistance* ; Insulin*

No abstract available.

Semmelweis correctly concluded that puerperal fever could be spread from necrotic discharge from living patients, as well as autopsy material. And maternal death rate was decreased dramatically by washing hands in chlorinated lime. Semmelweis may be credited with having for the first time constructed a statistically tested system of asepsis (keeping germs away from the patient) before the germ theory had arrived.
Asepsis ; Autopsy ; Fever ; Hand ; Humans ; Maternal Death*

No abstract available.
Minimally Invasive Surgical Procedures* ; Stomach Neoplasms*

No abstract available.
Cardiology*

Aged* ; Cardiovascular Diseases* ; Humans

BACKGROUND: The subcellular localization and activity of beta-catenin are tightly regulated within the cell. The aim of this study was to analyze the aberrant beta-catenin expression in breast carcinomas and to determine its clinical significance. METHODS: Fifty five cases of breast carcinoma were immunostained with monoclonal antibodies against beta-catenin. Normal expression of -catenin was defined as exclusive membranous staining. Abnormal expression of beta-catenin was reclassified into 3 categories: complete or partial loss of membranous staining (LOM) without cytoplasmic staining and nuclear staining, LOM with cytoplasmic staining and without nuclear staining, and LOM with nuclear staining and with/without cytoplasmic staining. RESULTS: Normal membranous beta-catenin expression was detected in 25 (45.5%) of 55 cases of breast carcinoma. Thirty cases with abnormal -catenin expression comprised 9 cases (16.1%) showing LOM without cytoplasmic and/or nuclear staining, 20 cases (36.4%) showing LOM with cytoplasmic staining and without nuclear staining, and one case (1.8%) showing LOM with nuclear and cytoplasmic staining. Abnormal beta-catenin expression was significantly correlated with lymph node metastasis (p=0.03). LOM with cytoplasmic and/or nuclear expression was significantly correlated with poor disease free survival by univariate (p=0.03) and multivariate analyses (p=0.03). In addition, it was correlated with poor overall survival with a borderline significance (p=0.059). CONCLUSIONS: This study suggests that the cytoplasmic and/or nuclear expression of beta-catenin can be used as a biologic marker for predicting disease recurrence and poor patients' survival in breast carcinomas.
Antibodies, Monoclonal ; beta Catenin ; Biomarkers ; Breast Neoplasms* ; Breast* ; Carcinoma, Ductal, Breast ; Cytoplasm ; Disease-Free Survival ; Immunohistochemistry ; Lymph Nodes ; Multivariate Analysis ; Neoplasm Metastasis ; Recurrence